Form 4: TransMedics Group Executive Tamer Khayal Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Tamer Khayal, Chief Commercial Officer of TransMedics Group, Inc., executed stock options to acquire common stock at prices of $13.28 and $16.14.
- Khayal then sold shares of common stock at a weighted average price of approximately $80.06 and $80.36.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
- Following these transactions, Khayal directly owns 25,185 shares of common stock and indirectly owns 14,776 shares through the Khayal Family 2021 Irrevocable Trust and 11,051 shares through the Tamer Ibrahim Ahmed Khayal Trust.
- He also holds options to purchase 26,947 shares at $13.28 and 12,729 shares at $16.14.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to utilize Rule 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The activity itself doesn't necessarily indicate a positive or negative outlook for the company.
Comparison to Industry Standards
- Executive compensation packages often include stock options as incentives.
- Rule 10b5-1 trading plans are a standard practice among publicly traded companies to allow insiders to sell shares in a pre-planned manner.
- The size and frequency of these transactions are typical for executives at similarly sized companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The impact on employees, customers, suppliers, and creditors is likely negligible.
Key Dates
| Date | Description |
|---|---|
| 09/06/2023 | Date of establishment of the Rule 10b5-1 trading plan |
| 02/22/2026 | Full vesting date for some stock options |
| 02/27/2030 | Expiration date for some stock options |
| 02/22/2032 | Expiration date for some stock options |
| 04/03/2024 | Date of first reported transaction (option exercise and stock sale) |
| 04/04/2024 | Date of second reported transaction (option exercise and stock sale) |
| 04/05/2024 | Date of signature of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.